3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Solid Tumors
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
enzalutamide
2
apalutamide
2
Pluvicto
2
Leuprolide
2
Androgen Antagonists
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relugolix
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
luprolide acetate gel depot
1
larotrectinib
1
ipatasertib
1
gallium 68 PSMA-11
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has announcements
×
Prostatic Neoplasms
×
entrectinib
×
Clear all
No trials found.